A private investment firm funded entirely by its partners based in the United States is looking to make equity investment into early and mid-stage life science companies ranging from $500,000 to 2 million initially. The firm looks to get involved in seed and series A rounds. The firm could make as many as 6 investments over the next 12 months and looks to invest in companies located throughout the United States, Europe and Israel.

The firm is currently interested in sectors of Therapeutics, and Diagnostics. The firm is open to review all types of molecules and platforms and is currently most interested in for companies working towards indications of autism, CNS disorders, and Parkinson’s disease. The firm generally looks to get involved with companies that are at the pre-clinical stage of development.

The firm is looking for companies with driven, and talented management teams with strong IP for their products. The firm is looking to invest in privately held companies and looks to take an active role following investment generally as a member of the board. The firm is very comfortable working with scientific founding teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities. The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including immunology, oncology, MS, and fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials. The firmis looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm located in the Northeastern United Sates is looking to make investments in the life sciences space, and does so on a case by case basis without a traditional fund structure. Since the members are investing their own capital, the investment size and capital structure are highly flexible and will depend on the financial needs of the company. However the minimum amount the fund is willing to invest is $2 million, and can go upwards of $40 million. The firm invests in private or public companies and prefers to be the lead investor, but is open to syndicate as well. The firm is willing to invest in opportunities from all across the Globe. The firm is looking to conduct as many investments as possible over the course of the next 12 months, and is open to qualified deal flow

The firm is very opportunistic and will consider a broad range of life science opportunities. The firm will consider biotech, medical technology, R&D services, however the firm prefers not to invest in healthcare IT, dermatology, or wound care. The firm focuses on companies with clinical assets with some efficacy data, through those who have products on the market are also considered. The firm has a strong interest in technologies that significantly improve the standard of care.

The firm evaluates the company’s management team on a case by case basis. The firm is open to working with both experienced teams, as well as new entrepreneurs, and only requires that the team be competent. The firm does not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a medical real estate firm is currently seeking to invest in stage medical device companies with at least one product on the market and in need of funding to grow sales and broaden their product offering. The firm seeks to allocate $250K to $2M (in equity or mezzanine) per company. The firm invests in companies that are based in the US and is currently seeking the final investment for its fund. 

The firm seeks to invest in medical devices that provide solutions to unmet orthopedic, neurosurgical, and gastroenterology problems. The firm is focus on improving patient outcomes with reducing delivery costs. The firm prefers Class I and II devices that are nearing or have regulatory approval. The company must have at least one product on the market to be considered.

The firm looks to act as a strategic partner following investment offering management expertise in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United State is currently investing out of its 2^nd million dollar fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however they firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United States is looking to invests in growth and expansion-stage technology and life science companies. The firm is currently investing from its inaugural fund and expects to close its second fund ($50M target) by the end of 2014. The firm prefers to make growth stage investments in Series C and D rounds, typically co-investing with other institutional investors. The investment size is variable depending on the company’s market capitalization. The firm focuses on companies that are located in regions underserved by venture capital such and the firm is actively seeking new investment opportunities.

In the life sciences the firm seeks to invest in therapeutics, medical devices, and diagnostics. The firm is opportunistic in terms of subsectors and indications. The firm seeks therapeutics that are at least in Phase III and medical devices that are very close to or with FDA approval. The firm historically invested in vitro diagnostic tests and medical imaging.

The firm generally co-invests with other top tier institutional investors and seeks companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital/incubation firm supports about 5 new early-stage life science companies per year, and provides two years of funding in return for equity.  Funding is only available to Israel-based companies; in cases where entrepreneurs based outside Israel would like to establish a company in Israel, an Israeli CEO/project manager is recruited by the firm.

The firm incubates medical device companies, and focuses on very early-stage ventures, including devices at or before the patent application stage; in such cases, the firm will help the innovator form a company and a management team.  The firm focuses on minimally invasive devices, and has experience of investing in cardiovascular devices, ophthalmology, orthopedic devices, laproscopic devices, and many other fields.  The firm is open to investing in any indication area.

The firm invests in companies targeting unmet medical needs with large markets, and seeks to invest in good management teams.  The firm prefers to invest in ventures that require $5m or less of R&D spending to reach the market.  As the the program provides funding for 2 years, the firm also helps its portfolio companies find additional funding to support future development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com